(UroToday.com) In this discussion, Dr. Alumkal discussed two presentations looking at molecular correlates of response to apalutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) and data from the ACIS trial of androgen annihilation with abiraterone and apalutamide in chemotherapy naïve mCRPC.